Jet Plasma Energy In Meibomian Gland Dysfunction Treatment

This retrospective study was conducted from March 2025 to December 2025 and included 90 patients presenting with moderate to severe meibomian gland dysfunction (MGD). 

All patients were aged between 40 and 75 years, with no sex preference. Patients underwent a standardized treatment protocol consisting of three sessions of Jet Plasma Energy Technology (JET), performed at intervals ranging from one to two weeks. JET was applied using electroporation, either as a standalone modality or in combination with platelet-rich plasma administered during the treatment session.

All patients underwent a comprehensive ocular surface evaluation prior to treatment, including meibography, corneal epithelial mapping, and tear film interferometry. Follow-up assessments were systematically performed at three and six months after completion of the treatment protocol. Clinical outcomes were evaluated based on symptomatology using the Ocular Surface Disease Index (OSDI) score, as well as objective improvements observed in epithelial mapping and interferometric parameters.

The results demonstrated a significant improvement in subjective symptoms, reflected by a marked reduction in OSDI scores, accompanied by measurable enhancement in epithelial regularity and tear film quality. 

These findings suggest that JET-based electroporation, whether used alone or in combination with platelet-rich plasma, represents an effective and well-tolerated therapeutic approach for patients with moderate to severe MGD.